In July 2015, The Salgi Esophageal Cancer Research Foundation awarded esophageal cancer research funding for the very first time. This feat was accomplished in less than five years since our inception.
The research was awarded to Dr. Carlos Minacapelli and his team of researchers. The study titled “Chemoprevention studies on an in-vitro Barrett’s Epithelium Carcinogenesis model targeting CYP1 biomarker(s) by natural product Curcumin” was completed at the Crohn’s and Colitis Center of New Jersey, Division of Gastroenterology, Department of Medicine, Rutgers Robert Wood Johnson Medical School.
The American Gastroenterological Association (AGA) Institute Council accepted Dr. Minacapelli’s abstract to be presented as a poster presentation on Monday, May 8, 2017, during Digestive Disease Week (DDW) held in Chicago, IL. The abstract is entitled “Effect of Benzo[a]pyrene along with Acid and Bile is highly carcinogenic as shown in the in-vitro Barrett’s Esophagus Carcinogenesis (BEC) model.”
We are proud to have been a part of this research and will continue to prioritize funding research of esophageal cancer until a cure is found. To learn more about our esophageal cancer research, our funding program and how you can help, please visit: salgi.org/research
Effect of Benzo[A]Pyrene Along with Acid and Bile is Highly Carcinogenic as Shown in Thein-Vitro Barrett’s Esophagus Carcinogenesis (BEC) Model
Minacapelli, Carlos D. et al.
Gastroenterology , Volume 152 , Issue 5 , S834 – S835
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The Salgi Esophageal Cancer Research Foundation 